Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Hydroxyurea Treatment for Sickle Cell Disease
source: St. Jude Children’s Research Hospital
year: N/A
summary/abstract:Hydroxyurea is a medicine that can help children and adults with sickle cell disease.
Research studies show that hydroxyurea lowers the following:
• The numbers of acute chest syndrome (pneumonia) events
• The number of pain crises
• The need for blood transfusions
• The number of trips to the hospital
Hydroxyurea also might prevent damage to the spleen, kidneys, lungs, and brain.
Hydroxyurea is given by mouth one (1) time each day. It comes in liquid or capsule form. The U.S. Food and Drug Administration (FDA) has approved it for the treatment of adults with severe sickle cell disease. St. Jude Children’s Research Hospital and other medical centers have carried out research studies that demonstrated the safety of hydroxyurea therapy for young children and infants with sickle cell disease.
read more
+myBinderRelated Content
-
FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
-
Chronic opioid therapy is more strongly associated with central sensitization in sickle cell disease than clinical p...Central nervous system sensitization (CS...
-
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell diseaseAs defined by the American Physical Ther...
-
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™Emmaus Life Sciences, Inc., a leader in ...
-
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
-
Don’t Let Sickle Cell Disease Limit Youhttps://www.onescdvoice.com/wp-content/u...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.